About taletrectinib adipate
ROS1 tyrosine kinase inhibitor
Used for
- Treats advanced ROS1-positive non-small cell lung cancer in adults.
Usual adult dose
600 mg by mouth once daily, on an empty stomach, until disease progression or unacceptable toxicity.
Common side effects
- Increased liver enzymes
- Nausea, vomiting, or constipation
- Dizziness or changes in taste
- Muscle pain or weakness
Important warnings
- Can cause serious liver injury; liver tests are monitored during treatment.
- May cause muscle injury; report unexplained muscle pain or weakness.
- Can cause dizziness or fainting; use caution with activities requiring alertness.
- Avoid grapefruit and strong interacting medicines that affect drug-metabolizing enzymes.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for two weeks afterward.
Breastfeeding
Do not breastfeed during treatment and for two weeks after the last dose.
Interactions
- Strong CYP3A inhibitors can increase taletrectinib levels.
- Strong CYP3A inducers can reduce taletrectinib levels.
- Taletrectinib can affect levels of medicines transported by P-glycoprotein or BCRP.
- Avoid grapefruit products.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.